Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||FGFR2 - DBP|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - DBP||intrahepatic cholangiocarcinoma||predicted - sensitive||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, Lytgobi (futibatinib) treatment at a dose of 20mg led to an objective response rate of 16.7% (7/42) and a median progression-free survival of 6 months in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, including a partial response with a progression-free survival of 10.9 months and a duration of response of 2 months in a patient harboring FGFR2-DBP (PMID: 34551969; NCT02052778).||34551969|